Investors pile onto TenNor IPO with hopes for new type of gastric drug
The biotech enjoyed a standout Hong Kong share debut after hailing its novel anti-bacterial drug, now undergoing late-stage clinical tests, as a potential gamechanger Key Takeaways: The TenNor Therapeutics IPO…
BRIEF: Heavily oversubscribed TenNor Therapeutics soars in trading debut
Shares of Biotechnology firm TenNor Therapeutics (Suzhou) Ltd. (6872.HK) nearly tripled in their Hong Kong debut on Friday, doubling when trading began and rising throughout the day to close at HK$211, up 179%.…
RELATED ARTICLES
-
Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- BRIEF: Heavily oversubscribed TenNor Therapeutics soars in trading debut
- Geneplus locks onto targeted medicine for IPO pitch
- Eye drug maker VivaVision feels the strain in IPO funding dash
- A healthy return: drug spin-off nets Keymed up to $320 million
- Jacobio Pharma poised to turn a profit from precision cancer drugs
